364 related articles for article (PubMed ID: 9878997)
1. Letrozole. A review of its use in postmenopausal women with advanced breast cancer.
Lamb HM; Adkins JC
Drugs; 1998 Dec; 56(6):1125-40. PubMed ID: 9878997
[TBL] [Abstract][Full Text] [Related]
2. Letrozole: a review of its use in postmenopausal women with breast cancer.
Simpson D; Curran MP; Perry CM
Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328
[TBL] [Abstract][Full Text] [Related]
3. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer.
Wiseman LR; Adkins JC
Drugs Aging; 1998 Oct; 13(4):321-32. PubMed ID: 9805213
[TBL] [Abstract][Full Text] [Related]
4. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
5. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Hamilton A; Piccart M
Ann Oncol; 1999 Apr; 10(4):377-84. PubMed ID: 10370778
[TBL] [Abstract][Full Text] [Related]
6. New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
de Jong PC; Blijham GH
Neth J Med; 1999 Aug; 55(2):50-8. PubMed ID: 10474272
[TBL] [Abstract][Full Text] [Related]
7. Pivotal trials of letrozole: a new aromatase inhibitor.
Smith IE
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):41-4. PubMed ID: 9556791
[TBL] [Abstract][Full Text] [Related]
8. Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
Clemett D; Lamb HM
Drugs; 2000 Jun; 59(6):1279-96. PubMed ID: 10882163
[TBL] [Abstract][Full Text] [Related]
9. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
10. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
Gershanovich M; Chaudri HA; Campos D; Lurie H; Bonaventura A; Jeffrey M; Buzzi F; Bodrogi I; Ludwig H; Reichardt P; O'Higgins N; Romieu G; Friederich P; Lassus M
Ann Oncol; 1998 Jun; 9(6):639-45. PubMed ID: 9681078
[TBL] [Abstract][Full Text] [Related]
11. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C
J Clin Oncol; 2001 Jul; 19(14):3357-66. PubMed ID: 11454883
[TBL] [Abstract][Full Text] [Related]
12. Role of anti-aromatase agents in postmenopausal advanced breast cancer.
Murray R
Cancer Chemother Pharmacol; 2001 Oct; 48(4):259-65. PubMed ID: 11710624
[TBL] [Abstract][Full Text] [Related]
13. [Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer].
Gershanovich M; Chaudri Kh; Campos D; Lurie H; Bonaventura A; Jeffrey M; Buzzi F; Bodrogi I; Ludwig H; Reichard P; O'Higgins NO; Romieu G; Friedrich P; Lassus M
Vopr Onkol; 1999; 45(4):361-8. PubMed ID: 10532092
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Rose C
Am J Clin Oncol; 2003 Aug; 26(4):S9-16. PubMed ID: 12902872
[TBL] [Abstract][Full Text] [Related]
15. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Buzdar A; Jonat W; Howell A; Jones SE; Blomqvist C; Vogel CL; Eiermann W; Wolter JM; Azab M; Webster A; Plourde PV
J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors in the treatment of postmenopausal breast cancer.
Bajetta E; Zilembo N; Bichisao E
Drugs Aging; 1999 Oct; 15(4):271-83. PubMed ID: 10582774
[TBL] [Abstract][Full Text] [Related]
17. Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients.
Trunet PF; Bhatnagar AS; Chaudri HA; Hornberger U
Acta Oncol; 1996; 35 Suppl 5():15-8. PubMed ID: 9142959
[TBL] [Abstract][Full Text] [Related]
18. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
Michaud LB; Buzdar AU
Drug Saf; 1999 Oct; 21(4):297-309. PubMed ID: 10514021
[TBL] [Abstract][Full Text] [Related]
19. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Buzdar AU; Robertson JF; Eiermann W; Nabholtz JM
Cancer; 2002 Nov; 95(9):2006-16. PubMed ID: 12404296
[TBL] [Abstract][Full Text] [Related]
20. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
Jonat W; Howell A; Blomqvist C; Eiermann W; Winblad G; Tyrrell C; Mauriac L; Roche H; Lundgren S; Hellmund R; Azab M
Eur J Cancer; 1996 Mar; 32A(3):404-12. PubMed ID: 8814682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
